文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Long-Term Outcomes of Breast Cancer Patients Who Underwent Selective Neck Dissection for Metachronous Isolated Supraclavicular Nodal Metastasis.

作者信息

Chen Shin-Cheh, Shen Shih-Che, Yu Chi-Chang, Huang Ting-Shuo, Lo Yung-Feng, Chang Hsien-Kun, Lin Yung-Chang, Kuo Wen-Ling, Tsai Hsiu-Pei, Chou Hsu-Huan, Lee Li-Yu, Huang Yi-Ting

机构信息

Department of General Surgery, Division of Breast Surgery, Chang Gung Memorial Hospital, Chang Gung University Medical College, Linkou Branch, Taoyuan 333, Taiwan.

Department of General Surgery, Chang Gung Memorial Hospital, Keelung Branch, Keelung 204, Taiwan.

出版信息

Cancers (Basel). 2021 Dec 29;14(1):164. doi: 10.3390/cancers14010164.


DOI:10.3390/cancers14010164
PMID:35008328
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8750885/
Abstract

We retrospectively enrolled 139 patients who developed metachronous isolated supraclavicular lymph node metastasis (miSLNM) from 8129 consecutive patients who underwent primary surgery between 1990 and 2008 at a single medical center. The median age was 47 years. The median follow-up time from date of primary tumor surgery was 73.1 months, and the median time to the date of neck relapse was 43.9 months in this study. Sixty-one (43.9%) patients underwent selective neck dissection (SND). The 5-year distant metastasis-free survival (DMFS), post-recurrence survival, and overall survival (OS) rates in the SND group were 31.1%, 40.3%, and 68.9%, respectively, whereas those of the no-SND group were 9.7%, 32.9%, and 57.7%, respectively ( = 0.001). No SND and time interval from primary tumor surgery to neck relapse ≤24 months were the only significant risk factors in the multivariate analysis of DMFS (hazard ratio (HR), 1.77; 95% confidence interval (CI), 1.23-2.56; = 0.002 and HR, 1.76, 95% CI, 1.23-2.52; = 0.002, respectively) and OS (HR, 1.77; 95% CI, 1.22-2.55; = 0.003 and HR, 3.54, 95% CI, 2.44-5.16; < 0.0001, respectively). Multimodal therapy, including neck dissection, significantly improved the DMFS and OS of miSLNM. Survival improvement after miSLNM control by intensive surgical treatment suggests that miSLNM is not distant metastasis.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8535/8750885/93ba5e8b1a4d/cancers-14-00164-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8535/8750885/7af7409f7ecc/cancers-14-00164-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8535/8750885/93ba5e8b1a4d/cancers-14-00164-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8535/8750885/7af7409f7ecc/cancers-14-00164-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8535/8750885/93ba5e8b1a4d/cancers-14-00164-g002.jpg

相似文献

[1]
Long-Term Outcomes of Breast Cancer Patients Who Underwent Selective Neck Dissection for Metachronous Isolated Supraclavicular Nodal Metastasis.

Cancers (Basel). 2021-12-29

[2]
Surgery for isolated regional failure in nasopharyngeal carcinoma after radiation: Selective or comprehensive neck dissection.

Laryngoscope. 2019-2

[3]
[The Role of Supraclavicular lymph node dissection in Breast Cancer Patients with Synchronous Ipsilateral Supraclavicular Lymph Node Metastasis].

Zhonghua Zhong Liu Za Zhi. 2017-5-23

[4]
Combined Therapy Can Improve the Outcomes of Breast Cancer with Isolated Supraclavicular Lymph Node Involvement.

Cancer Manag Res. 2020-11-19

[5]
Selective Neck Dissection and Survival in Pathologically Node-Positive Oral Squamous Cell Carcinoma.

Cancers (Basel). 2019-2-25

[6]
The prognostic value of selective neck dissection in early-stage major salivary gland carcinoma: a population-based analysis.

Front Oncol. 2024-5-22

[7]
Specific Selective Neck Dissection for Isolated Regional Failure in Nasopharyngeal Carcinoma after Radiation.

Ear Nose Throat J. 2025-9

[8]
Sinonasal squamous cell carcinoma without clinical lymph node involvement : Which neck management is best?

Strahlenther Onkol. 2016-8

[9]
Oncologic outcomes of selective neck dissection in HPV-related oropharyngeal squamous cell carcinoma.

Laryngoscope. 2017-3

[10]
Prognosis of breast cancer after supraclavicular lymph node metastasis: not a distant metastasis.

Ann Surg Oncol. 2006-11

引用本文的文献

[1]
Supraclavicular Lymph Node Dissection in Breast Cancer with Synchronous Supraclavicular Metastases: A Systematic Review and Network Meta-Analysis.

Cancers (Basel). 2025-6-21

[2]
The role of TET2 in solid tumors and its therapeutic potential: a comprehensive review.

Clin Transl Oncol. 2024-9

[3]
The Evolving Approach to Breast Cancer: Moving toward De-Escalating Treatment and Personalized Medicine.

Cancers (Basel). 2023-7-5

[4]
Clinical features combined with ultrasound-based radiomics nomogram for discrimination between benign and malignant lesions in ultrasound suspected supraclavicular lymphadenectasis.

Front Oncol. 2023-3-9

[5]
Transcriptome profiling for precision cancer medicine using shallow nanopore cDNA sequencing.

Sci Rep. 2023-2-9

本文引用的文献

[1]
Correction to: Impact of Ipsilateral Supraclavicular Lymph Node Dissection (ISLND) for Breast Cancer Patients and a Nomogram for Predicting Ipsilateral Supraclavicular Pathological Complete Response (ispCR).

Ann Surg Oncol. 2021-12

[2]
Comparison of Survival Outcomes Among Patients With Breast Cancer With Distant vs Ipsilateral Supraclavicular Lymph Node Metastases.

JAMA Netw Open. 2021-3-1

[3]
Survival and Prognostic Factors for Breast Cancer Patients with Regional Oligo-Recurrence.

J Breast Cancer. 2020-12

[4]
Combined Therapy Can Improve the Outcomes of Breast Cancer with Isolated Supraclavicular Lymph Node Involvement.

Cancer Manag Res. 2020-11-19

[5]
Comparison between surgery plus radiotherapy and radiotherapy alone in treating breast cancer patients with ipsilateral supraclavicular lymph node metastasis.

Gland Surg. 2020-10

[6]
Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial.

Lancet Oncol. 2020-12

[7]
Regional Lymph Node Involvement Among Patients With De Novo Metastatic Breast Cancer.

JAMA Netw Open. 2020-10-1

[8]
Clinicopathological features of breast cancer patients with internal mammary and/or supraclavicular lymph node recurrence without distant metastasis.

BMC Cancer. 2020-9-29

[9]
Treatment Patterns and Outcomes of Women with Breast Cancer and Supraclavicular Nodal Metastases.

Ann Surg Oncol. 2021-4

[10]
Clinicopathological Evaluation of the Potential Anatomic Pathways of Systemic Metastasis from Primary Breast Cancer Suggests an Orderly Spread Through the Regional Lymph Nodes.

Ann Surg Oncol. 2020-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索